[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Chatni SS, Sainani RS, Mehta SA, Mohandas KM: Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally-advanced and metastatic gallbladder cancer. J Cancer Res Ther; 2008 Oct-Dec;4(4):151-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally-advanced and metastatic gallbladder cancer.
  • BACKGROUND: Gallbladder cancer (GBC) has a poor prognosis.
  • Chemotherapy is traditionally considered to be ineffective.
  • MATERIALS AND METHODS: A total of 65 patients with inoperable GBC received palliative chemotherapy with CDDP and 5-FU.
  • Response was assessed after three cycles of chemotherapy.
  • RESULTS: A total of 19 patients had locally advanced unresectable cancer and 46 patients had metastatic cancer.
  • A total of 212 chemotherapy cycles were administered to the patients.
  • Response evaluation after three cycles of chemotherapy revealed complete response in five patients [7.69%; 95% confidence interval (95% CI): 2.87-16.22], partial response in 17 patients (26.15%; 95% CI: 16.57-37.81), stabilization of disease in 9 patients (13.85%; 95% CI: 6.96-23.88), and progression in 21 patients (32.30%; 95% CI: 21.80-44.35).
  • The median overall survival was 5.7 months and the median time to disease progression was 3.1 months.
  • This chemotherapy combination was well tolerated.
  • There were no chemotherapy-related deaths.
  • CONCLUSIONS: Infusion chemotherapy with CDDP and 5-FU appears to have a fair amount of activity in patients of inoperable GBC, with acceptable toxicity.
  • Tumor shrinkage following treatment with this regimen enabled surgical resection in two patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052386.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Galvão FH, Pestana JO, Capelozzi VL: Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. Cancer Chemother Pharmacol; 2010 Feb;65(3):607-10
MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.
  • Gemcitabine is a chemotherapy agent that may cause unpredictable side effects.
  • In this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma.
  • A 72-year-old patient was submitted to an elective laparoscopic cholecystectomy, and a tubular adenocarcinoma in the gallbladder was incidentally diagnosed.
  • CT scan and ultrasound before the surgery did not show any tumor.
  • The colonic lesion was conveniently removed and the histology evaluation confirmed the diagnosis of adenocarcinoma tubular.
  • Three weeks later he developed severe respiratory distress.
  • A helicoidal CT scan showed diffuse and severe interstitial pneumonitis, and lung biopsy confirmed accelerated usual interstitial pneumonia consistent with drug-induced toxicity.
  • He died 1 month later in spite of methylprednisolone pulse therapy, large spectrum antimicrobial therapy, and full support of respiratory, hemodynamic and renal systems.
  • Physicians should suspect pulmonary toxicity in patients with respiratory distress after gemcitabine chemotherapy, mainly in elderly patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Lung Diseases, Interstitial / chemically induced
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Fatal Outcome. Humans. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2002;20(7-8):876-9 [12449717.001]
  • [Cites] J Thorac Oncol. 2009 Jul;4(7):845-52 [19487963.001]
  • [Cites] Br J Dermatol. 1997 Feb;136(2):279-82 [9068751.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):286-91 [9217042.001]
  • [Cites] Cancer. 2006 May 1;106(9):2051-7 [16568459.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1759-60 [16685265.001]
  • [Cites] J Thorac Oncol. 2006 Jun;1(5):434-40 [17409896.001]
  • [Cites] Anticancer Drugs. 2007 Oct;18(9):1109-11 [17704662.001]
  • [Cites] Invest New Drugs. 2008 Feb;26(1):67-74 [17805486.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Jan;35(1):133-6 [18195543.001]
  • [Cites] Chest. 2008 Feb;133(2):528-38 [18252919.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(2):179-81 [18459559.001]
  • [Cites] Oncologist. 2008 Jul;13(7):807-11 [18614588.001]
  • [Cites] Hum Pathol. 2008 Sep;39(9):1275-94 [18706349.001]
  • [Cites] JOP. 2008;9(6):708-14 [18981552.001]
  • [Cites] Arch Gynecol Obstet. 2009 Feb;279(2):251-4 [18548263.001]
  • [Cites] Eur J Med Res. 2009;14:90-2 [19258219.001]
  • [Cites] Clin Pharmacol Ther. 1981 Aug;30(2):239-45 [7249508.001]
  • (PMID = 19904536.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


3. Mody K, Strauss E, Lincer R, Frank RC: Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer; 2010;10:570
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.
  • BACKGROUND: Gallbladder cancer typically follows an aggressive course, with chemotherapy the standard of care for advanced disease; complete remissions are rarely encountered.
  • The epidermal growth factor receptor (EGFR) is a promising therapeutic target but the activity of single agent oral EGFR tyrosine kinase inhibitors is low.
  • There have been no previous reports of chemotherapy plus an EGFR-tyrosine kinase inhibitor (TKI) to treat gallbladder cancer or correlations of response with the mutation status of the tyrosine kinase domain of the EGFR gene.
  • CASE PRESENTATION: A 67 year old man with metastatic gallbladder cancer involving the liver and abdominal lymph nodes was treated with gemcitabine (1000 mg/m2) on day 1 and 8 every 21 days as well as daily erlotinib (100 mg).
  • After four cycles of therapy, the CA 19-9 normalized and a PET/CT showed a complete remission; this response was maintained by the end of 12 cycles of therapy.
  • Gemcitabine was then discontinued and single agent erlotinib was continued as maintenance therapy.
  • The disease remains in good control 18 months after initiation of therapy, including 6 months on maintenance erlotinib.
  • Because of the remarkable response to erlotinib plus gemcitabine, we performed tumor genotyping of the EGFR gene for response predicting mutations in exons 18, 19 and 21.
  • This disclosed the wild-type genotype with no mutations found.
  • CONCLUSION: This case report demonstrates a patient with stage IV gallbladder cancer who experienced a rarely encountered complete, prolonged response after treatment with an oral EGFR-TKI plus chemotherapy.
  • These observations should inform the design of clinical trials using EGFR-TKIs to treat gallbladder and other biliary tract cancers; such trials should not select patients based on EGFR mutation status.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / genetics. Mutation. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Aged. CA-19-9 Antigen / biosynthesis. DNA Mutational Analysis. Erlotinib Hydrochloride. Exons. Humans. Lymphatic Metastasis. Male. Positron-Emission Tomography / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2010 Jan;11(1):48-54 [19932054.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1403-6 [11762811.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1237-45 [16078261.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7753-4; author reply 7754-5 [16234545.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):649-52 [16032426.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1680-5 [16551849.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] BMC Cancer. 2006;6:190 [16846514.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] Oncologist. 2010;15(2):168-81 [20147507.001]
  • (PMID = 20961434.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CA-19-9 Antigen; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2972285
  •  go-up   go-down


Advertisement
4. Amano A, Ohkawa S, Ueno M: [A case report of S-1 monotherapy as first-line treatment for metastatic gallbladder cancer]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1307-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of S-1 monotherapy as first-line treatment for metastatic gallbladder cancer].
  • We experienced a case of advanced gallbladder cancer with a remarkable response treated by oral fluoropyrimidine anticancer drug S-1 (120 mg/day on day 1 through 28 followed by a 14-day recovery period) as first-line chemotherapy.
  • The patient was enrolled in the late phase II trial of S-1 for metastatic biliary tract cancer designed to evaluate efficacy and safety.
  • The anti-tumor effect was observed in both primary lesion of gallbladder and metastatic lesion of liver,and the efficacy was confirmed to be a partial response (Japan Society for Cancer Therapy Criteria).
  • After the first two courses of treatment, the reduction ratio of the tumor volume was 88.1% in the measurable lesions of liver metastasis.
  • The patient continued the outpatient treatment for a total 7 courses.
  • The overall survival time was 470 days,suggesting that S-1 is highly effective and tolerable for metastatic gallbladder cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology. Liver Neoplasms / secondary. Oxonic Acid / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Drug Administration Schedule. Drug Combinations. Humans. Male. Quality of Life

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687220.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


5. Wagner AD, Buechner-Steudel P, Moehler M, Schmalenberg H, Behrens R, Fahlke J, Wein A, Behl S, Kuss O, Kleber G, Fleig WE: Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer; 2009 Dec 1;101(11):1846-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
  • BACKGROUND: Gemcitabine, oxaliplatin and 5-fluorouracil (5-FU) are active in biliary tract cancer and have a potentially synergistic mode of action and non-overlapping toxicity.
  • The objective of these trials was to determine response, survival and toxicity separately in patients with bile duct cancer (BDC) and gallbladder cancer (GBC) treated with gemcitabine/oxaliplatin/5-FU chemotherapy.
  • METHODS: Eligible patients with histologically proven, advanced or metastatic BDC (n=37) or GBC (n=35) were treated with gemcitabine (900 mg m(-2) over 30 min), oxaliplatin (65 mg m(-2)) and 5-FU (1500 mg m(-2) over 24 h) on days 1 and 8 of a 21-day cycle.
  • CONCLUSION: Triple-drug chemotherapy achieves comparable results for response and survival to previously reported regimens, but with more toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Jun 15;82(12):2321-5 [9635523.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):398-403 [15691639.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1650-4 [15856037.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7753-4; author reply 7754-5 [16234545.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2004 Nov;1(1):4-5 [16265019.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1152-60 [16505435.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] BMC Cancer. 2006;6:121 [16677397.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):82-7 [17030546.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Invest New Drugs. 2007 Aug;25(4):385-90 [17364234.001]
  • [Cites] Jpn J Clin Oncol. 2007 Nov;37(11):843-51 [17942578.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):418-25 [18087285.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):309-15 [18182984.001]
  • [Cites] Oncologist. 2008 Apr;13(4):415-23 [18448556.001]
  • [Cites] J Cancer Res Ther. 2008 Oct-Dec;4(4):151-5 [19052386.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):146-59 [18667395.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):862-7 [19238628.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3375-80 [11705850.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2229-39 [11980994.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):478-83 [14998852.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9 [7481849.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(2):117-23 [10412945.001]
  • (PMID = 19904267.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2788250
  •  go-up   go-down


6. Yoshida N, Kochi M, Funada T, Mamiya T, Ohkubo R, Kaiga T, Takayama T: [Elderly patient with metastatic gallbladder cancer treated by cisplatin, epirubicin and continuous infusion 5-fluorouracil]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2421-3
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Elderly patient with metastatic gallbladder cancer treated by cisplatin, epirubicin and continuous infusion 5-fluorouracil].
  • An 80-year-old woman, who was followed as an A-bomb victim, was diagnosed to have advanced gallbladder cancer with liver metastasis on December, 2005.
  • Therefore, her general condition was good, so we decided to treat her with cisplatin, epirubicin and continuous infusion of 5-fluorouracil(CEF therapy).
  • CEF therapy was started from February, 2007.
  • We tried chemotherapy with gemcitabine as a second-line treatment.
  • The result of gemcitabine was again a progressive disease, so we switched her regimen to S-1 as a third-line treatment on January, 2008.
  • Chemotherapy is continued by the outpatient care now, 25 months after the medical treatment started.
  • The present result suggests that CEF therapy may be useful for metastatic gallbladder cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Epirubicin / therapeutic use. Fluorouracil / therapeutic use. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology. Liver Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / blood. Female. Humans. Infusions, Intravenous. Lung Neoplasms / blood. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098415.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Chang TS, Liaw CC, Lee KF, Wu CS: Gingival metastasis from gallbladder cancer. Chang Gung Med J; 2002 Aug;25(8):553-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival metastasis from gallbladder cancer.
  • Gallbladder cancer is generally diagnosed at an advanced stage.
  • Oral soft tissue metastasis is extremely unusual.
  • This report describes the case of a 62-year-old woman diagnosed with advanced metastatic gallbladder cancer, who initially presented with abdominal pain.
  • Diagnosis of gallbladder cancer was made about 3 months after her symptoms developed, when a laparoscopic cholecystectomy was performed because of the suspicion of gallstones.
  • A visible left gingival tumor was found on physical examination and was confirmed as gallbladder cancer metastasis by compatible histopathology 1 month after surgery.
  • The patient responded poorly to chemotherapy and unfortunately died 5 months after the diagnosis.
  • The clinical presentation of gallbladder cancer was relatively typical, apart from the unusual gingival metastasis.
  • The medical literature contains quite a few examples of metastatic lesions located strictly in the oral soft tissue, however no case of gallbladder cancer metastasizing to the oral soft tissue has been previously reported.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Gingival Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12392369.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


8. Teufel A, Lehnert T, Stremmel W, Rudi J: Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma. Z Gastroenterol; 2000 Nov;38(11):909-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma.
  • BACKGROUND: Advanced or metastatic gallbladder carcinoma is regarded not much sensitive to chemotherapy.
  • Standard chemotherapy regimens have not been established up to now.
  • PATIENTS: We report on 5 patients with advanced gallbladder carcinoma who received chemotherapy with gemcitabine.
  • Only one patient had no benefit from treatment with gemcitabine.
  • CONCLUSION: We conclude that gemcitabine may be an effective drug in the palliative treatment of gallbladder cancer, and thus its efficiency warrants evaluation in further studies.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cholecystectomy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132538.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. Matsuda T, Shikata S, Minato H, Aikawa I: [Two cases of advanced biliary tract cancer successfully treated with gemcitabine combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Oct;35(10):1779-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced biliary tract cancer successfully treated with gemcitabine combination chemotherapy].
  • CT scans revealed cancerous pleuritis in March 2005, and he was treated with the chemotherapy of GEM alone as first-line, combined chemotherapy of S-1 and GEM as second-line, and CDDP and GEM as third-line treatment.
  • These therapies have been effective for about 20 months.
  • Case 2: A woman in her sixties was diagnosed with advanced gallbladder cancer(stage IVb)in September 2005.
  • She was given combined chemotherapy of S-1+GEM as first-line, and CDDP+GEM as second-line treatment.
  • The main tumor and metastatic lymph nodes were shrunk, allowing us to perform extended hepatectomy.
  • Histopathologic examinations of the resected specimen of the liver involved by the tumor showed the increased infiltration of inflammatorycells and fibrosis.
  • These patients have been managed on an outpatient basis with good QOL and cancer controlled.
  • Although there has been no established standard regimen, the combined chemotherapy based on GEM will be a provisional standard regimen for patients with advanced biliarytract cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Biliary Tract Neoplasms / pathology. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Biomarkers, Tumor / blood. Female. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931588.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. Abahssain H, Afchain P, Melas N, Ismaili N, Rahali R, Rabti HM, Errihani H: [Chemotherapy in gallbladder carcinoma]. Presse Med; 2010 Dec;39(12):1238-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy in gallbladder carcinoma].
  • [Transliterated title] Chimiothérapie dans le cancer de la vésicule biliaire.
  • Gallbladder cancer is an aggressive tumor.
  • Surgery is the standard treatment for localized stage but there is no standard treatment in metastatic or locally advanced disease.
  • Because of the rarity of bile tract cancer (BTC) and gallblader carcinoma (GBC), most studies have grouped all BTC and GBC together, and there are very few GBC-specific studies.
  • Adjuvant therapy after surgical resection is not validated.
  • Understanding the molecular mechanisms of carcinogenesis of GBC has opened the way for the use of targeted therapies.
  • This new treatment would improve survival and quality of life of our patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Capecitabine. Cisplatin / administration & dosage. Cisplatin / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Invasiveness. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21074352.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Yoneto T, Yoshikawa K, Fujii Y: [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine]. Gan To Kagaku Ryoho; 2005 Jan;32(1):99-102
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
  • A 79-year-old female patient was referred to our hospital for treatment of a recurrent gallbladder cancer.
  • Before admission, she had undergone expanded cholecystectomy and had been treated successfully with 5-FU for 3 years to suppress the tumor growth in intraperitoneal lymph nodes.
  • The recurrence of the tumor in lymph nodes near the pancreas head was demonstrated by computer tomography.
  • We tried a course of a combination chemotherapy consisting of CPT-11 and CDDP (40 mg CPT-11/body/day on day 1 and 10 mg CDDP/body/day on day 2-5) to reduce the size of the nodes.
  • Then, we repeated a total of 8 courses of the therapy at 4-week intervals.
  • So, we substituted gemcitabine (1 g/body/day) for the combination chemotherapy with expandable metallic stent implantation to drain the bile.
  • As a result, metastatic lymph nodes were reduced in size and the dilatation of the interhepatic bile duct disappeared.
  • Thereafter, the patient was given an additional 20 courses of gemcitabine therapy at 2-week intervals as an outpatient.
  • No change was observed in the size of the metastatic lymph nodes for a year.
  • However, the patient died of liver metastasis 8 years after operation and 6 years after she started chemotherapy for the recurrence.
  • She maintained a good quality of life during that time.
  • The present case suggests that combination of chemotherapy protocols is effective for clinical management of gallbladder cancer recurrence, which is generally considered to be difficult to manage with chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Lymph Nodes / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Survivors

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15675592.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Nakadaira K, Kurosaki I, Ueki H: [Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification]. Gan To Kagaku Ryoho; 2008 May;35(5):837-9
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
  • We described a case with recurrent gallbladder carcinoma, successfully treated by combination chemotherapy using gemcitabine, CPT-11, and S-1 that was administered as second-line chemotherapy after failure of gemcitabine monotherapy.
  • The level of CA19-9 was normalized three months later, and metastatic tumors of the liver were calcified.
  • She had received the combination chemotherapy for 15 months and is now alive.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Calcinosis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Female. Humans. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Neoplasm Recurrence, Local. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487925.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Hada M, Horiuchi T, Shinji H: [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]. Gan To Kagaku Ryoho; 2006 Feb;33(2):259-61
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
  • Gallbladder cancer is an asymptomatic disease in the early stage and no therapeutic measure is available except surgical intervention.
  • The prognosis for patients with advanced,i.e., unresectable or metastatic disease is dismal, with median survival usually being less than 6 months if not treated with chemotherapy.
  • To date, chemotherapy for gallbladder cancer has been limited by the absence of agents with effective cytotoxic activity.
  • Thalidomide has been shown to have antiangiogenic and immunomodulatory effects, including the inhibition of vascular endothelial growth factor, basic fibroblast growth factor and tumor necrosis factor alpha.
  • The reported biological consequences of COX-2 up-regulation include inhibition of apoptosis, increased metastatic potential and promotion of angiogenesis.
  • These events may contribute to cell transformation and tumor progression.
  • Antiangiogenesis represents a significant new strategy for cancer treatment.
  • Here we show a case of unresectable gallbladder cancer with remarkable improvement in CA19-9 and prolongation of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Celecoxib. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Humans. Liver Neoplasms / pathology. Male. Neoplasm Invasiveness. Peritoneal Neoplasms / secondary. Prognosis. Pyrazoles / administration & dosage. Remission Induction. Sulfonamides / administration & dosage. Thalidomide / administration & dosage

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484869.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 0W860991D6 / Deoxycytidine; 4Z8R6ORS6L / Thalidomide; B76N6SBZ8R / gemcitabine; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


14. Yoshida R, Matsuda T, Watanabe T, Iwadou H, Hunabiki K, Kamikawa Y: [A case of gallbladder cancer which completely responded to gemcitabine]. Gan To Kagaku Ryoho; 2010 Sep;37(9):1771-3
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gallbladder cancer which completely responded to gemcitabine].
  • A 7 9-year-old man with advanced gallbladder cancer (stage IVa) underwent chemotherapy with single-agent gemcitabine (1,400mg/body: day 1, 8, 15, every 4 weeks) as first-line chemotherapy.
  • As soon as the chemotherapy started, the carbohydrate antigen 19-9 (CA19-9) level was notably reduced, and after 4 courses, CT scan revealed that the tumor was markedly reduced in size.
  • Intraoperative findings revealed that the gallbladder atrophied and, with no obvious invasion to adjacent organs, a small hard mass like only fibrosis was confirmed.
  • In the histological findings, cancer tissue was replaced by fibrosis, and malignant cells could not be detected.
  • Many clinical trials show that gemcitabine, which is used as a single agent or combined with other agents (for example, cisplatin), demonstrated high efficacy with manageable toxicity in patients with advanced or metastatic biliary tract cancer.
  • For this disease, including gallbladder cancer, gemcitabine is the mainstay of chemotherapy, and it is thought that this agent could have high efficacy in many cases.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20841944.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


15. Garg PK, Khurana N, Hadke NS: Subcutaneous and breast metastasis from asymptomatic gallbladder carcinoma. Hepatobiliary Pancreat Dis Int; 2009 Apr;8(2):209-11
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous and breast metastasis from asymptomatic gallbladder carcinoma.
  • BACKGROUND: Though gallbladder carcinoma is associated with early lymphatic and hematogenous spread, the only common extra-abdominal site of metastasis is lung.
  • Gallbladder carcinoma metastasizing to breast and subcutaneous tissue is not known.
  • METHOD: This report describes an interesting and unusual case of asymptomatic gallbladder carcinoma presenting with subcutaneous and breast metastasis.
  • Fine needle aspiration cytology (FNAC) of these nodules revealed metastatic adenocarcinoma.
  • The patient was investigated for a primary neoplasm.
  • An ultrasound of the abdomen followed by a contrast-enhanced CT scan showed a growth in gallbladder, infiltrating the liver with multiple hepatic metastases.
  • CT-guided FNAC from the growth in the gallbladder revealed adenocarcinoma.
  • She was diagnosed as a case of metastatic adenocarcinoma of the gallbladder and palliative combination chemotherapy with gemcitabine and carboplatin was given.
  • But she developed jaundice and deteriorated dramatically in a short span of time.
  • No specific therapy could be started and she was given supportive treatment.
  • She died within three weeks of diagnosis due to hepatic encephalopathy.
  • CONCLUSIONS: This report highlights an unusual metastasis of gallbladder carcinoma to the breast and subcutaneous tissue presenting as multiple lesions, which has never been reported in the English literature.
  • These were unknown sites of metastasis for carcinoma of the gallbladder.
  • Moreover, bilateral multiple metastatic lesions to breast are also very rare.
  • [MeSH-major] Breast Neoplasms / secondary. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Female. Gallbladder Neoplasms / pathology. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357037.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK: Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol; 2007 Aug;60(3):321-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
  • BACKGROUND: Biliary tract cancer is one of the most aggressive and chemotherapy-refractory tumors.
  • Although only curative treatment modality is surgery, most patients are not suitable for surgery due to advanced stage of the disease at diagnosis.
  • Thus most patients with biliary tract cancer are possible candidates for palliative chemotherapy.
  • We performed a phase II study of combination chemotherapy with capecitabine and cisplatin in these patients to evaluate efficacy and toxicity of the regimen.
  • METHODS: Patients with previously untreated metastatic, recurrent, or inoperable biliary tract cancer were enrolled.
  • Response was assessed for every two cycles of chemotherapy and treatment was stopped when tumor had progressed or stable with no further response.
  • Fifteen patients (46.9%) had gallbladder cancer, 13 (40.6%) had intrahepatic cholangiocarcinoma, and 4 (12.5%) had extrahepatic biliary cancer.
  • The most frequent metastatic sites were lymph nodes (20/32, 62.5%) and liver (28/32, 56.3%).
  • The median time to progression was 3.5 months (95% CI, 1.3-5.8), and the median overall survival was 12.4 months (95% CI, 6.3-18.5) after the median follow-up duration of 9.5 months (4.8-26.1 months).
  • A total of 108 cycles of chemotherapy was delivered.
  • There was no treatment-related death.
  • CONCLUSION: The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Metastasis. Recurrence. Survival Analysis

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143602.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Alberts SR, Fishkin PA, Burgart LJ, Cera PJ, Mahoney MR, Morton RF, Johnson PA, Nair S, Goldberg RM, North Central Cancer Treatment Group: CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer; 2002;32(2-3):107-14
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.
  • BACKGROUND: Bile-duct and gallbladder carcinomas are rare cancers.
  • Once they have spread beyond the point of surgical resectability, no therapies have shown meaningful long-term benefit.
  • These cancers are typically refractory to standard chemotherapy agents.
  • Based on preclinical work showing activity of CPT-11, we performed a phase II trial to assess its activity in patients with bile-duct or gallbladder carcinomas.
  • METHODS: Patients with histologic or cytologic evidence of locally advanced or metastatic bile-duct or gallbladder carcinoma were potentially eligible for this study.
  • Patients meeting study eligibility and who signed an informed consent were given CPT-11 125 mg/m2 weekly for 4 wk followed by a 2-wk break from therapy.
  • Patients continued on treatment if they showed evidence of benefit and tolerated therapy.
  • CONCLUSION: CPT-11 is ineffective therapy for patients with locally advanced or metastatic bile-duct or gallbladder carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Bile Duct Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Carcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12794246.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Hejna M, Zielinski CC: Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy. Expert Rev Anticancer Ther; 2001 Aug;1(2):291-300
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy.
  • Carcinoma of the gallbladder is a rare tumor entity.
  • Apart from surgical intervention, there is no therapeutic measure with curative potential.
  • Therefore, patients with advanced--i.e., unresectable or metastatic-disease present a difficult problem to clinicians, whether to choose a strictly symptomatic treatment or expose the patient to the side effects of potentially ineffective treatment.
  • Since there is no standard therapy for advanced gallbladder cancer, patients should be offered the opportunity to participate in controlled clinical trials.
  • [MeSH-major] Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Controlled Clinical Trials as Topic. Hepatic Artery. Humans. Infusions, Intra-Arterial. Neoplasm Staging. Palliative Care. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12113034.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 68
  •  go-up   go-down


19. Doval DC, Bhatia K, Pavithran K, Sharma JB, Vaid AK, Hazarika D: Breast carcinoma with metastasis to the gallbladder: an unusual case report with a short review of literature. Hepatobiliary Pancreat Dis Int; 2006 May;5(2):305-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma with metastasis to the gallbladder: an unusual case report with a short review of literature.
  • Gallbladder metastases are very rare and usually arise from malignant melanoma, renal cell carcinoma and cervical carcinoma.
  • Breast carcinoma metastatic to the gallbladder is extremely rare and only 4 cases have been reported in the English literature.
  • One month after the operation, she developed acute abdominal pain and underwent cholecystectomy after clinical investigation.
  • Histopathological examination revealed metastasis to the gallbladder.
  • Being considered a patient with metastatic breast carcinoma she was subjected to taxane and anthracycline-based palliative chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / secondary. Gallbladder Neoplasms / secondary. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698597.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 15
  •  go-up   go-down


20. Hertl M, Cosimi AB: Liver transplantation for malignancy. Oncologist; 2005 Apr;10(4):269-81
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver transplantation for hepatic malignancies has emerged from an exotic and desperate approach to a well-documented and proven treatment modality for these unfortunate patients.
  • Currently, <10% of all liver transplants performed are for hepatocellular cancer (HCC).
  • Similarly, liver transplantation for HCC in the adult population yields good results for patients whose tumor masses do not exceed the Milan criteria.
  • It remains to be determined whether patients with more extensive tumors can be reliably selected to benefit from the procedure.
  • Adjunctive procedures like radiofrequency ablation, chemoembolization, or cryotherapy might be indicated to limit tumor progression for patients on waiting lists.
  • Metastatic liver disease is not an indication for liver transplantation, with the exception of cases in which the primary is a neuroendocrine tumor, for which liver transplantation can result in long-term survival and even cure in a number of patients.
  • And finally, while gallbladder cancers are never an indication for liver transplantation, rare cases of cholangiocellular cancer might qualify if aggressive combination therapies, including chemotherapy and radiotherapy followed by OLT, are carried through.
  • [MeSH-minor] Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Hemangioendothelioma, Epithelioid / mortality. Hemangioendothelioma, Epithelioid / pathology. Hemangioendothelioma, Epithelioid / surgery. Hepatoblastoma / mortality. Hepatoblastoma / pathology. Hepatoblastoma / surgery. Humans. Medical Oncology / trends. Neoplasm Metastasis. Patient Selection. Survival Rate. Treatment Outcome. Waiting Lists

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15821247.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


21. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS: Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer; 2005 Dec 15;104(12):2753-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
  • BACKGROUND: Biliary tract carcinoma is an aggressive cancer, with median survival rarely exceeding 6 months.
  • A Phase II trial was conducted to study a combination of oral capecitabine and gemcitabine (CapGem) as first-line therapy in patients with advanced and/or metastatic biliary carcinoma.
  • METHODS: Patients with unresectable or metastatic intrahepatic or extrahepatic biliary duct carcinoma and gallbladder carcinoma were enrolled.
  • Eligible patients had histologically or cytologically confirmed, measurable adenocarcinoma and had not received prior therapy with capecitabine or gemcitabine.
  • Treatment consisted of intravenous (i.v.) gemcitabine (1000 mg/m(2) on Days 1 and 8) plus oral capecitabine (650 mg/m(2) twice daily on Days 1-14) every 3 weeks for up to 6 cycles.
  • Tumor response, survival, and safety were determined.
  • Primary tumor sites were: intrahepatic (n = 14) and extrahepatic biliary duct (n = 16); gallbladder (n = 7); and ampulla (n = 7).
  • Median time to disease progression and overall survival were 6.0 (range, 3.8-8.1) and 14 (range, 11.4-16.6) months, respectively.
  • CONCLUSIONS: CapGem is an active and well tolerated first-line combination chemotherapy regimen for patients with advanced/metastatic biliary tract carcinoma that offers a convenient home-based therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / secondary
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bone Neoplasms / secondary. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16294346.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report].
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • Five years after the patient presented with melena and acute anemia; during endoscopic examination, a large bleeding duodenal polyp was found, so a surgical resection of the gastric antrum, duodenum, head of the pancreas, main bile ducts and gallbladder was performed.
  • RESULTS: Microscopically, the tumor mass showed a mostly fasciculated architecture, composed of spindle and epithelioid cells in a scarce fibromyxoid stroma, featuring large areas of coagulative necrosis and small foci of sclerohyalinosis.
  • Tumor cells featured large vesciculous nuclei, with a few prominent nucleoli; no foci of osteoid matrix were detectable.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Osteosarcoma / secondary. Tibia

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Karachaliou N, Polyzos A, Kentepozidis N, Kakolyris S, Ziras N, Vardakis N, Kalykaki A, Milaki G, Georgoulias V, Androulakis N: A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract. Oncology; 2010;78(5-6):356-60
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract.
  • PURPOSE: To evaluate the efficacy and tolerability of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) as first-line treatment of advanced biliary tract cancer.
  • The median overall survival time was 9.2 months (95% CI 5.8-12.5) and the median progression-free survival time 2.7 months (95% CI 2.2-3.2).
  • There were no treatment-related deaths.
  • CONCLUSION: The combination of oxaliplatin and irinotecan has a modest antitumor activity with manageable toxicity as first-line treatment in metastatic cancer of the biliary tract and therefore it cannot be recommended as front-line treatment for unresectable biliary tract cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Biliary Tract Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Ampulla of Vater / pathology. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / pathology. Female. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright ©2010 S. Karger AG, Basel.
  • (PMID = 20798557.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. van der Hoeven J, Busch O, Bijnen C, Gouma D, van Gulik T: [Diagnosis and treatment of carcinoma of the gall bladder]. Ned Tijdschr Geneeskd; 2010;154:A355
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of carcinoma of the gall bladder].
  • Over the past decade considerable progress has been made in several fields relating to the diagnosis and treatment of gall bladder cancer.
  • This literature search evaluates if these recent advances have led to improved diagnosis, treatment and survival of patients with gall bladder carcinoma.
  • Current radiotherapy and chemotherapy in adjuvant and neoadjuvant settings have not shown any survival benefit.
  • For T3-tumours, only those patients without metastatic disease will benefit from an additional resection.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cholecystectomy. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20356434.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 28
  •  go-up   go-down


25. Pavithran K, Doval DC, Vaid AK, Verma RN: Small cell carcinoma of the gall bladder: case report and review of literature. Trop Gastroenterol; 2001 Jul-Sep;22(3):170-1
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell carcinoma of the gall bladder is a very rare tumor.
  • The neoplasm is highly lethal, metastasizes early, and may cause death shortly after diagnosis.
  • Here we report a 56 year old male with small cell carcinoma of the gall bladder metastatic to the liver.
  • He attained partial remission with 5 fluouracil, cisplatin based chemotherapy.
  • However, the disease progressed after 3 months and salvage chemotherapy with docetaxel and caboplatin failed to produce any tumour response.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Gallbladder Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11681116.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 14
  •  go-up   go-down


26. André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer; 2008 Sep 16;99(6):862-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced biliary tract carcinomas (BTCs) are often diagnosed at an advanced/metastatic stage and have a poor prognosis.
  • This international phase II study evaluated the efficacy and safety of GEMOX as first-line therapy in patients with advanced BTCs.
  • Eligible patients with previously untreated locally advanced or metastatic BTC received gemcitabine 1000 mg m(-2) (day 1) and oxaliplatin 100 mg m-2 (day 2), every 2 weeks.
  • Seventy patients were enroled; 72.9% had metastatic disease.
  • The objective response rate was 20.5% in patients with non-gallbladder cancers (9/44 patients) and 4.3% in patients with gallbladder cancers (1/23).
  • In this study, GEMOX demonstrated activity in non-gallbladder carcinoma, but poor activity in gallbladder carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease-Free Survival. Female. Humans. International Agencies. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / therapeutic use. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Oncology. 2006;70(4):280-4 [17047399.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1307-12 [17628484.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):47-52 [17364190.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):564-70 [17597402.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):621-7 [19672264.001]
  • [Cites] BMC Cancer. 2002 May 3;2:10 [11991810.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16 [12577228.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):478-83 [14998852.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(2):117-23 [10412945.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7753-4; author reply 7754-5 [16234545.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jun;21(6):999-1003 [16724985.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii68-72 [16760298.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):848-52 [16969352.001]
  • [Cites] CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64 [11760569.001]
  • (PMID = 19238628.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; gemcitabine-oxaliplatin regimen
  • [Other-IDs] NLM/ PMC2538748
  •  go-up   go-down






Advertisement